Pneumonia: Clinical Trials

85 trials for Pneumonia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 25 unknown, 6 terminated, 5 not yet recruiting. 85 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 185Completed 36, Unknown 25, Terminated 6, Not yet recruiting 5, Withdrawn 5, Recruiting 4, Suspended 3, Active not recruiting 1

Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia

Trials (filtered) newest first · largest first

All 85 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Role of Inhaled Polymyxin as an Adjunct to Intravenous Therapy in Multidrug Resistant Ventilator-associated Pneumonia in Stroke Patients
Inhaled colistin, Saline - Ventilator Associated Pneumonia ( VAP)
Early Phase 1Not yet recruitingAin Shams University782026-10-102026-10-08
Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia
YHDF placebo, Bacteriophage Placebo, YHDF Drug - Pneumonia
Early Phase 1Not yet recruitingChinese PLA General Hospital2502026-06-012026-05-29
3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT
Amoxicillin - Community Acquired Pneumonia, Childhood Pneumonia
Early Phase 1Not yet recruitingKhyber Teaching Hospital2502026-06-012026-06-15
iNO300 Therapy in Critically Ill Patients With Pneumonia
High dose inhaled nitric oxide, Sham treatment, standard therapy - Critical Illness, Pneumonia
Early Phase 1RecruitingMassachusetts General Hospital342026-02-232026-05-22
A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli
YHDF Drug, YHDF Placebo, Bacteriophage - Pneumonia
Early Phase 1Not yet recruitingChinese PLA General Hospital2402026-02-012026-01-13
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) - PASC Post Acute Sequelae of COVID-19
Early Phase 1RecruitingUniversity of California, Davis512025-12-042026-05-22
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH) - COVID-19
Early Phase 1WithdrawnUniversity of California, Irvine2025-06-012024-11-05
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use - Covid19
Early Phase 1Active not recruitingHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair202025-05-182026-06-10
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
KFD1(0µg ), KFD1(20µg), KFD1(40µg) - COVID - 19
Early Phase 1Not yet recruitingShanghai Public Health Clinical Center602024-12-302025-01-10
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3 - SARS-CoV-2 Infection
Early Phase 1CompletedHvivo362024-12-022025-11-21
Long COVID-19 [11C]CPPC Study
[11C]CPPC Injection - COVID Long-Haul
Early Phase 1CompletedJohns Hopkins University62024-08-062026-04-30
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine - COVID - 19
Early Phase 1CompletedPrince of Songkla University362024-03-012025-12-04
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg - COVID-19 Pandemic, COVID-19 Vaccines
Early Phase 1UnknownDr. Soetomo General Hospital4002024-01-292024-02-14
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
Liraglutide Pen Injector [Saxenda], Medication Diary - Multiple Sclerosis, Long COVID
Early Phase 1SuspendedUniversity of Chicago302024-01-262026-03-30
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
low dose PCV24, high dose PCV24, PPV23 - Streptococcus Pneumoniae Pneumonia
Early Phase 1CompletedJiangsu Province Centers for Disease Control and Prevention2402023-11-182025-06-18
Piloting Virtual Reality Environments to Treat PTSD in Healthcare Workers
Virtual Reality Exposure Therapy - Posttraumatic Stress Disorder
Early Phase 1RecruitingWeill Medical College of Cornell University202023-10-052026-09-16
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg - COVID-19 Pandemic, COVID-19 Vaccines
Early Phase 1UnknownDr. Soetomo General Hospital2502023-09-192024-02-22
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
LYB002V14, LYB002V14A, LYB002CA - COVID-19
Early Phase 1UnknownGuangzhou Patronus Biotech Co., Ltd.2102023-04-252023-07-03
SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects
APR002, Placebo - COVID-19
Early Phase 1CompletedGlobal Health Drug Discovery Institute422023-03-202023-08-02
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19
MSC-derived exosomes - Long COVID-19 Syndrome
Early Phase 1UnknownHuazhong University of Science and Technology802023-02-152023-04-14

Showing 20 of 85. Sign in to see all of them.

Narrower conditions

COVID-19 (57)  ·  Pneumonia, Ventilator-Associated (7)  ·  Coronavirus Infections (6)  ·  Post-Acute COVID-19 Syndrome (6)  ·  Community-Acquired Pneumonia (3)  ·  Critical Illness (3)  ·  Respiratory Insufficiency (3)  ·  Dyspnea (2)  ·  Influenza, Human (2)  ·  Pneumonia, Viral (2)  ·  Pulmonary Disease, Chronic Obstructive (2)  ·  Respiratory Tract Infections (2)  ·  Severe Acute Respiratory Syndrome (2)  ·  Stress Disorders, Post-Traumatic (2)

Broader conditions

Infections (85)  ·  Lung Diseases (84)  ·  Respiratory Tract Diseases (84)  ·  Respiratory Tract Infections (83)  ·  Virus Diseases (62)  ·  Coronaviridae Infections (61)  ·  Nidovirales Infections (61)  ·  RNA Virus Infections (61)  ·  Pneumonia, Viral (60)  ·  Coronavirus Infections (55)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Disease Attributes (18)  ·  Pathologic Processes (18)  ·  Chronic Disease (8)

Interventions

COVID-19 Serotherapy (5)  ·  Hydroxychloroquine (4)  ·  Amoxicillin (3)  ·  Saline Solution (3)  ·  vaksin merah putih - UA SARS-CoV-2 COVID-19 vaccine (3)  ·  Acetylcysteine (2)  ·  Azithromycin (2)  ·  Endotoxins (2)  ·  Lipopolysaccharides (2)  ·  Sodium Chloride (2)  ·  Standard of Care (2)  ·  sinovac COVID-19 vaccine (2)  ·  2,5-dichloro-4-bromophenol (1)  ·  APR002 (1)  ·  Alanine (1)

Sponsors

Washington University School of Medicine (4)  ·  Dr. Soetomo General Hospital (3)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (2)  ·  Azidus Brasil (2)  ·  Chinese PLA General Hospital (2)  ·  Guangzhou Patronus Biotech Co., Ltd. (2)  ·  Lahore General Hospital (2)  ·  Livzon Pharmaceutical Group Inc. (2)  ·  University of California, Davis (2)  ·  University of Chicago (2)  ·  ASST Fatebenefratelli Sacco (1)  ·  Ain Shams University (1)  ·  Amazon University (1)  ·  Baylor College of Medicine (1)  ·  Binhui Biopharmaceutical Co., Ltd. (1)

Countries

United States (33)  ·  China (13)  ·  Brazil (3)  ·  Canada (3)  ·  Indonesia (3)  ·  Mexico (3)  ·  Pakistan (3)  ·  United Kingdom (3)  ·  Egypt (2)  ·  France (2)  ·  Australia (1)  ·  Belgium (1)  ·  Greece (1)  ·  Hungary (1)  ·  Iraq (1)

Top investigators

Delphine L Chen, MD (2)  ·  Muhammad Irfan Malik, FCPS (2)  ·  Xiaolan Yong, Bachelor (2)  ·  Aaron Weitzman (1)  ·  Adam DuVall, MD (1)  ·  Beatrice Stefanescu, MD, MS (1)  ·  Bill Gurley, PhD (1)  ·  Craig Selzman, MD (1)  ·  David Alland, MD (1)  ·  David Hager, MD PhD (1)  ·  David Landers, MD (1)  ·  Dean J Kereiakes, MD (1)  ·  Delphine Chen, MD (1)  ·  Dominicus Husada, MD (1)  ·  Erika Saunders, MD (1)

Results publications

PMID 34013969, PMID 36734509, PMID 37162745, PMID 15060237, PMID 18945956, PMID 19462133, PMID 19574441, PMID 21340319, PMID 23582727, PMID 23608625, PMID 24013700, PMID 24646034, PMID 25321315, PMID 25607427, PMID 25900158, PMID 26352946, PMID 26492219, PMID 27146253, PMID 27183377, PMID 27420164, PMID 28621712, PMID 29414995, PMID 32020029, PMID 32091533, PMID 32094336, PMID 32109013, PMID 32142651, PMID 32150618, PMID 32167747, PMID 32228809, PMID 32294342, PMID 32379955, PMID 32475230, PMID 32619759, PMID 32627860, PMID 32665041, PMID 32673071, PMID 33044747, PMID 33059771, PMID 33108255, PMID 33155953, PMID 33232211, PMID 33296901, PMID 33301246, PMID 33306989, PMID 33323376, PMID 33353987, PMID 33378609, PMID 33482902, PMID 33519466

NIH funding

R01AI185685 (1), R01HL151685 (1)